GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Travel & Leisure » Evoke PLC (LSE:EVOK) » Definitions » Cash per Share

Evoke (LSE:EVOK) Cash per Share : £0.57 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Evoke Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Evoke's Cash per Share for the quarter that ended in Dec. 2023 was £0.57.


Evoke Cash per Share Historical Data

The historical data trend for Evoke's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Cash per Share Chart

Evoke Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.23 0.51 0.71 0.57

Evoke Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.67 0.71 0.71 0.57

Evoke Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Evoke's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Evoke's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evoke  (LSE:EVOK) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Evoke Cash per Share Related Terms

Thank you for viewing the detailed overview of Evoke's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke (LSE:EVOK) Business Description

Traded in Other Exchanges
Address
Europort Road, Suite 601/701, Europort, GIB
888 Holdings PLC is an online betting and gaming company. The company operates in three business segments; The Retail segment comprises all activity undertaken in LBOs including gaming machines, The UK Online segment comprises all online activity, including sports betting, casino, poker, and other gaming products along with telephone betting services that are incurred within the UK and Ireland, and The International segment comprises all online activity, including sports betting, casino, poker, and other gaming products along with telephone betting services that are incurred within all territories excluding the UK. It derives a majority of its revenue from the United Kingdom.

Evoke (LSE:EVOK) Headlines

From GuruFocus

Evoke Pharma Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-15-2023

Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

By Stock market mentor Stock market mentor 01-30-2023

New GIMOTI Patent Listed in FDA Orange Book

By sperokesalga sperokesalga 05-01-2023